Provider of a digital therapeutics program based on diabetes prevention program clinical trial designed to pioneer digital behavior change. The company's digital therapeutics program is made to manage and change behavior around food, fitness, stress and helps health plan organizations to identify the population at risk for developing preventable chronic diseases, enabling people to change their habits, improve their health and reduce their risk of chronic disease.
Generating Revenue
Privately Held (backing)
Venture Capital-Backed
The company raised $50 million of venture funding in a round led by Cigna (NYSE: CI) on May 10, 2017, putting the pre-money valuation at $270 million. Civilization Ventures, Sanofi Genzyme BioVentures, U.S. Venture Partners, Andreessen Horowitz, Norwest Venture Partners, Humana, Kaiser Permanente Ventures, Providence Ventures, dRx Capital and GE Ventures also participated in this round.
Add a review